Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

New England Journal of Medicine

Volumn 344, Issue 25, 2001, Pages 1879-1887

  Cannon, Christopher P ^a   Weintraub, William S ^b   Demopoulos, Laura A ^c   Vicari, Ralph ^d   Frey, Martin J ^e   Lakkis, Nasser ^f   Neumann, Franz Josef ^g   Robertson, Debbie H ^c   Delucca, Paul T ^c   Dibattiste, Peter M ^c   Gibson, C Michael ^h   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EMORY UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Holmes Regional Medical Center   (United States)

^e Heart Center of Sarasota   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; EXERCISE TEST; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; TYROSINE;

EID: 0035927970     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106213442501     Document Type: Article

References (38)

1. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)
2. Aspirin, heparin, or both to treat acute unstable angina
3. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
4. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis
5. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
6. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial
7. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction
8. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
9. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy: Results of the Medicine versus Angiography in Thrombolytic Exclusion (MATE) trial
10. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
11. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial
12. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
13. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
14. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
15. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
16. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
17. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: Rationale and study design of the international TACTICS-TIMI 18 Trial
18. Unstable angina: A classification
19. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
20. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
21. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
22. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
23. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction)
24. Diagnosing and managing unstable angina
25. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms)
26. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
27. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes
28. Eptifibatide reduces the size and incidence of myocardial infarction in patients with non-ST-elevation acute coronary syndromes
29. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation
30. Benefit of tirofiban + heparin therapy in unstable angina/non-Q-wave myocardial infarction patients is observed regardless of interventional treatment strategy
31. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: Insights from the Platelet IIb/ IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial
32. The prognostic value of serum troponin T in unstable angina
33. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
34. Cardiac troponin T levels for risk stratification in acute myocardial ischemia
35. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection
36. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI-11B substudy
37. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
38. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban